Evaluation of the anaphylactoid activity of a new LHRH antagonist.
ORF 23541 [N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Pal(3)3,Ser4,Nic-Lys5,D-Nic-Lys 6, Leu7, I-Lys8, Pro9,D-Ala10NH2; "Nal-Lys antagonist"] was identified as a potent LHRH antagonist without significant anaphylactoid activity. It blocked ovulation in proestrus rats when administered subcutaneously with an ED50 of 5.8 micrograms/kg. Much higher doses of ORF 23541 than of other antagonists were required to induce a cutaneous anaphylactoid-like reaction. Intradermal administration of ORF 23541 caused an 8.75 x 8.75 mm wheal response with estimated doses of 10.9 and 13.7 micrograms in rats and guinea pigs, respectively. These doses were at least 10 times greater than that required of other LHRH antagonists for the same response. ORF 23541 also did not alter pulmonary function in guinea pigs or dogs when administered intravenously at doses up to 10 mg. These results indicate that ORF 23541 represents a new generation of LHRH antagonists with an improved safety margin.
D000707:Anaphylaxis / Q000139:chemically induced*; D000818:Animals; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006168:Guinea Pigs; D008168:Lung / Q000187:drug effects; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology* / Q000633:toxicity; D010060:Ovulation / Q000187:drug effects; D012123:Pulmonary Ventilation / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains
D009842:Oligopeptides; D007987:Gonadotropin-Releasing Hormone; C057022:iturelix